



**OUTCOME STATEMENT  
of the IMDRF-19 Management Committee  
16 to 25 March 2021**

The nineteenth meeting of the Management Committee (MC) of the International Medical Device Regulators Forum (IMDRF) took place over web conference from 16<sup>th</sup> to 25<sup>th</sup> March 2021. The meeting was chaired by the Republic of Korea. The MC consists of regulators from Australia, Brazil, Canada, China, the European Union (EU), Japan, Russia, Singapore, South Korea and the United States of America (USA). Representatives of the World Health Organization (WHO) and the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK)\* participated as Official Observers.

**Joint Workshop**

On Tuesday, March 16<sup>th</sup>, the IMDRF-DITTA Joint Virtual Workshop “What to learn from COVID-19” was held. 446 stakeholders registered for the virtual workshop. Regulators, industry representatives and healthcare providers shared challenges in the fight against COVID-19 and exchanged views on the lessons learned from the pandemic to improve regulatory frameworks for medical devices to support more resilient supply chains for future crises. This was followed by a panel discussion on how to maximize collaboration between regulators and industry and also amongst regulators and bring together best practices.

**Open MC Session**

On Thursday, March 18<sup>th</sup>, the open session of the MC meeting was held to provide an opportunity for the global industry associations, Global Diagnostic Imaging, Healthcare IT & Radiation Therapy Trade Association (DITTA) and the Global Medical Technology Alliance (GMTA) to engage with the MC members and Official Observers. The Asia-Pacific Economic Cooperation Life Sciences Innovation Forum Regulatory Harmonization Steering Committee (APEC LSIF RHSC), the Asian Harmonization Working Party/Global Harmonization Working Party (AHWP/GHWP) and the Pan American Health Organization (PAHO) as Regional Harmonization Initiatives (RHIs) and Swissmedic as an Invited Observer participated. Discussion focused on the IMDRF Strategic Plan for 2021-25 and topics for potential training proposals.

**Open Stakeholder Forum**

On Tuesday, March 23<sup>rd</sup>, a Virtual Open Stakeholder Forum was held. 545 representatives from regulatory authorities, industry and the research community, etc. registered for the Forum. Due to time constraints of the webinar and to enable better interaction with stakeholders, the presentation materials were made available to participants beforehand for them to review and submit questions for panel discussion at the Forum.

---

\* The UK was accepted as Official Observer by the MC on 21 January 2021.

The presentation materials provided regulatory updates from each MC member country, Official Observers and each of IMDRF's eight current working groups.

The IMDRF's eight current working groups are:

- a. Regulated Product Submission – Canada
- b. Good Regulatory Review Practice – USA/Singapore
- c. Medical Device Adverse Event Terminology – Japan
- d. Personalized Medical Devices – Australia
- e. Medical Device Clinical Evaluation – China
- f. Medical device Cybersecurity Guide – Canada/USA
- g. Principles of In Vitro Diagnostics (IVD) Medical Device Classification – Russia
- h. Artificial Intelligence Medical Devices – South Korea

Presentation materials were also provided to update on the work of:

1. World Health Organization (WHO)
2. APEC LSIF Regulatory Harmonization Steering Committee (RHSC)
3. Asian/Global Harmonization Working Party (AHWP/GHWP)
4. Pan American Health Organization (PAHO)
5. Global Diagnostic Imaging, Healthcare IT & Radiation Therapy Trade Association (DITTA)
6. Global Medical Technology Alliance (GMTA)
7. Korea Medical Devices Industry Association (KMDIA)
8. Korea Medical Devices Industrial Cooperative Association (KMDICA)
9. American Society for Testing and Materials (ASTM) International

The Forum comprised 3 segments where the panel addressed the questions received from participants:

1. Regulatory updates by IMDRF regulatory authority members
2. Progress of IMDRF work items
3. Stakeholders session

### **Closed MC Session**

At the closed session of the MC meeting on March 25<sup>th</sup>, the MC discussed and made decisions regarding the documents put forward from current working groups, New Work Item Extensions proposed by MC members, IMDRF SOP and other procedural matters (See Annex).

## ANNEX

### DECISIONS BY THE IMDRF MANAGEMENT COMMITTEE

In summary:

- The MC approved the Final N65 document, “Post-Market Clinical Follow-Up Studies”, of the Medical Device Clinical Evaluation (MDCE) Working Group.
- The MC approved the NWIE, “Evolution of the In Vitro Diagnostics and Non-In Vitro Diagnostics Devices Market Authorization Table of Contents”, of the Regulated Product Submission (RPS) Working Group, and also agreed on the co-chairmanship of Canada and the USA.
- The MC approved the NWIE, “Development of a reporting model for medical device regulatory reviews conducted by conformity assessment bodies (CABs)”, of the Good Regulatory Review Practice (GRRP) Working Group.
- The MC approved the 7th Edition of IMDRF Standard Operating Procedures.
- The MC has identified GHTF/IMDRF technical documents requiring review, and revisions of these documents will take place in accordance with the IMDRF Standard Operating Procedures.
- The MC continued the discussions on the implementation table and agreed to keep updating the table.
- The MC continued the discussions on the harmonization of medical devices nomenclature.